Mechanism of Action (MOA)
Epidyolex provides a different way to treat seizures vs. conventional anti-epileptic drugs (AEDs):1
- Structurally distinct from other AEDs
- Reduces neuronal hyper-excitability and inflammation through multiple MOAs
- Does not exert its anticonvulsant effects through interaction with cannabinoid receptors
Epidyolex has a novel MOA, providing a valuable new approach to treating seizures. The precise mechanisms by which cannabidiol exerts its anticonvulsant effects in humans are unknown.1
Reduction of neuronal hyper-excitability via 3 main actions (theoretical):
Discover the results
Epidyolex has been assessed in a large, controlled Phase III clinical trial programme within LGS and DS, including 714 patients.1
References
1. Epidyolex Summary of Product Characteristics (Date accessed: 03/09/2020).